

# Ulcerative colitis and clinical course: Results of a 5-year (the IBSEN study)

Inflammatory Bowel Diseases

12, 543-550

DOI: 10.1097/01.mib.0000225339.91484.fc

Citation Report

#	ARTICLE	IF	CITATIONS
1	Developing a novel risk-scoring system for predicting relapse in patients with ulcerative colitis: A prospective cohort study. Pakistan Journal of Medical Sciences, 1969, 31, 1511-6.	0.6	1
2	Changes in Clinical Characteristics, Course, and Prognosis of Inflammatory Bowel Disease during the Last 5 Decades: A Population-Based Study from Copenhagen, Denmark. Inflammatory Bowel Diseases, 2007, 13, 481-489.	1.9	340
3	Pediatric inflammatory bowel disease: Clinical and molecular genetics. Inflammatory Bowel Diseases, 2007, 13, 1430-1438.	1.9	66
4	Forecasting the recurrence of ulcerative colitis: Can U.C. the future?. Inflammatory Bowel Diseases, 2008, 14, 422-424.	1.9	2
5	What is the prognosis of ulcerative colitis?. Inflammatory Bowel Diseases, 2008, 14, S52-S53.	1.9	6
6	Predictive factors associated with immunosuppressive agent use in ulcerative colitis: a caseâ€“control study. Alimentary Pharmacology and Therapeutics, 2008, 28, 606-613.	3.7	22
7	Definition of Phenotypic Characteristics of Childhood-Onset Inflammatory Bowel Disease. Gastroenterology, 2008, 135, 1114-1122.	1.3	784
8	Clinical course of ulcerative colitis. Digestive and Liver Disease, 2008, 40, S247-S252.	0.9	32
9	Natural History of Severe Ulcerative Colitis in a Community-Based Health Plan. Clinical Gastroenterology and Hepatology, 2008, 6, 999-1003.	4.4	52
10	Ulcerative proctitis: a review of pharmacotherapy and management. Expert Opinion on Pharmacotherapy, 2008, 9, 741-749.	1.8	29
11	Response to Dr. Ze-Zhou Song. American Journal of Gastroenterology, 2008, 103, 241-241.	0.4	0
12	Intestinal Macrophage/Epithelial Cell-Derived CCL11/Eotaxin-1 Mediates Eosinophil Recruitment and Function in Pediatric Ulcerative Colitis. Journal of Immunology, 2008, 181, 7390-7399.	0.8	146
13	What is the prognosis of ulcerative colitis?. Inflammatory Bowel Diseases, 2008, 14, S52-S53.	1.9	0
14	Clinical factors that impair health-related quality of life in ulcerative colitis patients vary with the disease duration. European Journal of Gastroenterology and Hepatology, 2008, 20, 634-641.	1.6	11
16	Infliximab for the treatment of ulcerative colitis. Expert Review of Gastroenterology and Hepatology, 2009, 3, 219-229.	3.0	30
17	The Natural History of Pediatric Ulcerative Colitis: A Population-Based Cohort Study. American Journal of Gastroenterology, 2009, 104, 2080-2088.	0.4	273
18	Natural historyâ€“an optimistic message from Norway. Nature Reviews Gastroenterology and Hepatology, 2009, 6, 387-388.	17.8	1
19	Pediatric Inflammatory Bowel Disease: Is It Different?. Digestive Diseases, 2009, 27, 212-214.	1.9	43

#	ARTICLE	IF	CITATIONS
20	History of medical hospitalization predicts future need for colectomy in patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 176-181.	1.9	67
21	Pain and inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 778-788.	1.9	224
22	Risk factors and characteristics of extent progression in ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1320-1325.	1.9	63
23	Influence of Phenotype at Diagnosis and of Other Potential Prognostic Factors on the Course of Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2009, 104, 371-383.	0.4	267
24	Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). <i>Scandinavian Journal of Gastroenterology</i> , 2009, 44, 431-440.	1.5	628
25	Surgery in Ulcerative Colitis: Indication and Timing. <i>Digestive Diseases</i> , 2009, 27, 335-340.	1.9	81
26	Clinical Epidemiology of Ulcerative Colitis in Mexico. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 221-224.	2.2	42
27	Ulcerative colitis in the Tuzla region of Bosnia and Herzegovina between 1995 and 2006: epidemiological and clinical characteristics. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 346-353.	1.6	13
28	Need for standardization in population-based quality of life studies. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 525-536.	1.9	18
29	Ulcerative colitis in a Southern European country: A national perspective. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 822-829.	1.9	15
30	Genetic predictors of medically refractory ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1830-1840.	1.9	135
31	Infliximab for refractory ulcerative proctitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 1178-1185.	3.7	42
32	HLA-DRB1 alleles are associated with the clinical course of disease and steroid dependence in Mexican patients with ulcerative colitis. <i>Colorectal Disease</i> , 2010, 12, 1231-1235.	1.4	9
33	The Asia-Pacific consensus on ulcerative colitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 453-468.	2.8	134
34	Intestinal Protozoa Infections among Patients with Ulcerative Colitis: Prevalence and Impact on Clinical Disease Course. <i>Digestion</i> , 2010, 82, 18-23.	2.3	73
35	Is Inflammatory Bowel Disease More Severe when It Appears at Younger Ages?. <i>Digestion</i> , 2010, 81, 235-236.	2.3	0
36	Review: Current trends in inflammatory bowel disease: the natural history. <i>Therapeutic Advances in Gastroenterology</i> , 2010, 3, 77-86.	3.2	73
37	An Association Between Dietary Arachidonic Acid, Measured in Adipose Tissue, and Ulcerative Colitis. <i>Gastroenterology</i> , 2010, 139, 1912-1917.	1.3	83

#	ARTICLE	IF	CITATIONS
38	Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. <i>Gut</i> , 2010, 59, 49-54.	12.1	484
39	Epidemiology and Natural History of Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2011, 140, 1785-1794.e4.	1.3	1,718
40	Literature review and recommendations for clinical application of Colon Capsule Endoscopy. <i>Digestive and Liver Disease</i> , 2011, 43, 251-258.	0.9	17
41	Protective role of interleukin-19 gene polymorphisms in patients with ulcerative colitis. <i>Human Immunology</i> , 2011, 72, 1029-1032.	2.4	33
42	Pediatric Inflammatory Bowel Disease (IBD): Phenotypic, Genetic and Therapeutic Differences between Early-Onset and Adult-Onset IBD. <i>Korean Journal of Pediatric Gastroenterology and Nutrition</i> , 2011, 14, 1.	0.2	13
43	Identifying predictors of low health-related quality of life among patients with inflammatory bowel disease: comparison between Crohn's disease and ulcerative colitis with disease duration. <i>Journal of Clinical Nursing</i> , 2011, 20, 1578-1587.	3.0	48
44	Genetics of childhood-onset inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 346-361.	1.9	63
45	Current misunderstandings in the management of ulcerative colitis. <i>Gut</i> , 2011, 60, 1294-1299.	12.1	39
46	Clinical application of the multigene analysis test in discriminating between ulcerative colitis and Crohn's disease: a retrospective study. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 162-169.	1.5	10
47	Cost Utility of Inflammation-Targeted Therapy for Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 1143-1151.	4.4	16
48	Surgical and nonsurgical hospitalization rates and charges for patients with ulcerative colitis in Italy: A 10-year cohort study. <i>Digestive and Liver Disease</i> , 2012, 44, 369-374.	0.9	12
49	Prognostic Value of Serologic and Histologic Markers on Clinical Relapse in Ulcerative Colitis Patients With Mucosal Healing. <i>American Journal of Gastroenterology</i> , 2012, 107, 1684-1692.	0.4	234
50	Surgical treatment of ulcerative colitis in the biologic therapy era. <i>World Journal of Gastroenterology</i> , 2012, 18, 1861.	3.3	42
51	Colon capsule endoscopy: Advantages, limitations and expectations. Which novelties?. <i>World Journal of Gastrointestinal Endoscopy</i> , 2012, 4, 99.	1.2	40
52	Health-Related Quality of Life in Patients with Ulcerative Colitis After a 10-year Disease Course: Results from the IBSen Study. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1540-1549.	1.9	92
53	Inflammatory bowel disease in Asia: A systematic review. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1266-1280.	2.8	283
54	Inflammatory bowel disease in patients with primary sclerosing cholangitis: Clinical characterization in liver transplanted and nontransplanted patients. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 536-545.	1.9	109
55	Review of the disease course among adult ulcerative colitis population-based longitudinal cohorts. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 573-583.	1.9	116

#	ARTICLE	IF	CITATIONS
56	Managing chronic disease in Ireland: hospital admission rates and clinical outcomes in a large ulcerative colitis population. Irish Journal of Medical Science, 2012, 181, 65-71.	1.5	7
57	Relationship between non-adherence to aminosalicylate medication and the risk of clinical relapse among Japanese patients with ulcerative colitis in clinical remission: a prospective cohort study. Journal of Gastroenterology, 2013, 48, 1006-1015.	5.1	32
58	Genetic polymorphisms of interleukin 20 (IL-20) in patients with ulcerative colitis. Immunology Letters, 2013, 149, 50-53.	2.5	13
59	The burden of inflammatory bowel disease in Europe. Journal of Crohn's and Colitis, 2013, 7, 322-337.	1.3	781
60	Clinical Course of Intestinal Behçet's Disease During the First Five Years. Digestive Diseases and Sciences, 2013, 58, 496-503.	2.3	51
61	Personalizing therapy for inflammatory bowel diseases. Expert Review of Gastroenterology and Hepatology, 2013, 7, 549-558.	3.0	10
62	Risk of Surgery for Inflammatory Bowel Diseases Has Decreased Over Time: A Systematic Review and Meta-analysis of Population-Based Studies. Gastroenterology, 2013, 145, 996-1006.	1.3	670
64	Immunosuppression After Liver Transplantation for Primary Sclerosing Cholangitis Influences Activity of Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2013, 11, 517-523.	4.4	57
65	Review article: strategies for the management of chronic unremitting ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2013, 38, 77-97.	3.7	34
66	Incidence and Phenotype of Inflammatory Bowel Disease Based on Results From the Asia-Pacific Crohn's and Colitis Epidemiology Study. Gastroenterology, 2013, 145, 158-165.e2.	1.3	633
67	Prevalence of Corticosteroids Use and Disease Course After Initial Steroid Exposure in Ulcerative Colitis. Digestive Diseases and Sciences, 2013, 58, 2963-2969.	2.3	35
68	Pediatric inflammatory bowel disease: Can patterns in Asia shed some light?. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 387-389.	2.8	1
69	Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation - a placebo-controlled study. Alimentary Pharmacology and Therapeutics, 2013, 38, 264-273.	3.7	61
70	First Prospective, Population-Based Inflammatory Bowel Disease Incidence Study in Mainland of China. Inflammatory Bowel Diseases, 2013, 19, 1.	1.9	94
71	Phenotype of Inflammatory Bowel Disease at Diagnosis in the Netherlands. Inflammatory Bowel Diseases, 2013, 19, 2215-2222.	1.9	41
72	Fecal Calprotectin Levels Predict the Clinical Course in Patients With New Onset of Ulcerative Colitis. Inflammatory Bowel Diseases, 2013, 19, 576-581.	1.9	54
73	Peroxisome Proliferator-Activated Receptors Family Is Involved in the Response to Treatment and Mild Clinical Course in Patients with Ulcerative Colitis. Disease Markers, 2014, 2014, 1-7.	1.3	22
74	Anaemia in inflammatory bowel disease: a population-based 10-year follow-up. Alimentary Pharmacology and Therapeutics, 2014, 39, 69-76.	3.7	55

#	ARTICLE	IF	CITATIONS
75	Hospitalisation, surgical and medical recurrence rates in inflammatory bowel disease 2003â€“2011â€”A Danish population-based cohort study. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1675-1683.	1.3	54
76	Expression of interleukin (IL)-19 and IL-24 in inflammatory bowel disease patients: a cross-sectional study. <i>Clinical and Experimental Immunology</i> , 2014, 177, 64-75.	2.6	58
77	Early corticosteroids requirement after the diagnosis of ulcerative colitis diagnosis can predict a more severe longâ€”term course of the disease â€”a nationwide study of 1035 patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 374-381.	3.7	36
78	Standardized Recording of Parameters Related to the Natural History of Inflammatory Bowel Disease: From Montreal to Paris. <i>Digestive Diseases</i> , 2014, 32, 337-344.	1.9	13
79	What Have We Learnt about the Role of the Environment and Natural Course of IBD in the New Millennium? 20-Year Follow-Up of the IBSEN Cohort. <i>Digestive Diseases</i> , 2014, 32, 2-9.	1.9	9
80	Drug Therapies for Ulcerative Proctitis. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 2157-2178.	1.9	21
81	The Burden of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 545-552.	1.9	106
82	An Overview of the Natural History of Inflammatory Bowel Diseases. <i>Digestive Diseases</i> , 2014, 32, 320-327.	1.9	44
83	Refractory Distal Ulcerative Colitis: Is Proctocolectomy Always Necessary?. <i>Digestive Diseases</i> , 2014, 32, 110-115.	1.9	0
84	Proximal disease extension and related predicting factors in ulcerative proctitis. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 177-183.	1.5	47
85	Risk Matrix for Prediction of Advanced Disease in a Population-based Study of Patients with Crohn's Disease (the IBSEN Study). <i>Inflammatory Bowel Diseases</i> , 2014, 20, 60-68.	1.9	46
86	Epidemiology of inflammatory bowel disease: Focus on Asia. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 363-372.	2.4	120
87	Association of the interleukin 15 (IL-15) gene polymorphisms with the risk of developing ulcerative colitis in Mexican individuals. <i>Molecular Biology Reports</i> , 2014, 41, 2171-2176.	2.3	13
88	Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. <i>Gut</i> , 2014, 63, 423-432.	12.1	282
89	Editorial: early corticosteroids in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 727-727.	3.7	2
90	Intravenous corticosteroids in moderately active ulcerative colitis refractory to oral corticosteroids. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1523-1528.	1.3	17
91	Ulcerative proctitis: an update on the pharmacotherapy and management. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1565-1573.	1.8	18
92	DOP044 Patient education in a 14 month randomized trial fails to improve adherence in ulcerative colitis: Influence of demographic and clinical parameters on non-adherence. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S36.	1.3	5

#	ARTICLE	IF	CITATIONS
93	Disease severity in familial cases of IBD. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 234-239.	1.3	22
94	Presentation and Progression of Childhood-Onset Inflammatory Bowel Disease in Northern Stockholm County. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1098-1108.	1.9	42
95	Prevalence and Risk Factors for Therapy Escalation in Ulcerative Colitis in the Swiss IBD Cohort Study. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1.	1.9	11
96	The role of endoscopy in inflammatory bowel disease. <i>Journal of Digestive Diseases</i> , 2015, 16, 689-698.	1.5	5
97	Very Early-onset Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1166-1175.	1.9	82
98	Endoscopic Evaluation of Surgically Altered Bowel in Patients with Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1.	1.9	13
99	Patterns and Predictors of Long-term Nonuse of Medical Therapy Among Persons with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1615-1622.	1.9	13
100	Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: A prospective, randomized, controlled study. <i>United European Gastroenterology Journal</i> , 2015, 3, 72-79.	3.8	45
101	Integrins and adhesion molecules as targets to treat inflammatory bowel disease. <i>Current Opinion in Pharmacology</i> , 2015, 25, 67-71.	3.5	21
102	Risk matrix model for prediction of colectomy in a population-based study of ulcerative colitis patients (the IBSEN study). <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 1456-1462.	1.5	44
103	Health-related Quality of Life in Inflammatory Bowel Disease in a European-wide Population-based Cohort 10 Years After Diagnosis. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 337-344.	1.9	59
104	Inflammatory Bowel Disease. <i>Surgical Clinics of North America</i> , 2015, 95, 1105-1122.	1.5	148
105	Can narrow-band imaging of Peyer's patches predict the recurrence of ulcerative colitis?. <i>Intestinal Research</i> , 2016, 14, 295.	2.6	0
106	Inflammatory Bowel Disease: Crohn's disease and ulcerative colitis. <i>Deutsches Arzteblatt International</i> , 2016, 113, 72-82.	0.9	111
107	Health-related Quality of Life in Patients with Inflammatory Bowel Disease 20 Years After Diagnosis. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1679-1687.	1.9	35
108	Patients with longstanding ulcerative colitis in remission do not have more irritable bowel syndrome-like symptoms than controls. <i>BMC Gastroenterology</i> , 2016, 16, 139.	2.0	2
109	Interleukin 27 is up-regulated in patients with active inflammatory bowel disease. <i>Immunologic Research</i> , 2016, 64, 901-907.	2.9	23
110	Protective role of Interleukin 27 (IL-27) gene polymorphisms in patients with ulcerative colitis. <i>Immunology Letters</i> , 2016, 172, 79-83.	2.5	24

#	ARTICLE	IF	CITATIONS
111	Clinical Aspects of Idiopathic Inflammatory Bowel Disease: A Review for Pathologists. Archives of Pathology and Laboratory Medicine, 2016, 140, 413-428.	2.5	20
112	Evaluation of pouches and stomas. Techniques in Gastrointestinal Endoscopy, 2016, 18, 152-157.	0.3	1
113	Malignancies in Patients with Inflammatory Bowel Disease: Results from 20 Years of Follow-up in the IBSen Study. Journal of Crohn's and Colitis, 2017, 11, jcw193.	1.3	28
114	Rates and Reasons for Nonuse of Prescription Medication for Inflammatory Bowel Disease in a Referral Clinic. Inflammatory Bowel Diseases, 2016, 22, 919-924.	1.9	11
115	Low colectomy rate five years after diagnosis of ulcerative colitis. Results from a prospective population-based cohort in Sweden (ICURE) diagnosed during 2005-2009*. Scandinavian Journal of Gastroenterology, 2016, 51, 1339-1344.	1.5	27
116	Mortality and Causes of Death in Ulcerative Colitis. Inflammatory Bowel Diseases, 2016, 22, 141-145.	1.9	14
117	Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. Digestive and Liver Disease, 2016, 48, 360-370.	0.9	34
118	Twice-daily Budesonide 2-mg Foam Induces Complete Mucosal Healing in Patients with Distal Ulcerative Colitis. Journal of Crohn's and Colitis, 2016, 10, 828-836.	1.3	42
119	Treat to Target in Inflammatory Bowel Disease. Current Treatment Options in Gastroenterology, 2016, 14, 61-72.	0.8	29
120	Early Course of Inflammatory Bowel Disease in a Population-Based Inception Cohort Study From 8 Countries in Asia and Australia. Gastroenterology, 2016, 150, 86-95.e3.	1.3	94
121	The Natural History of Inflammatory Bowel Disease. , 2017, , 301-309.		0
122	Patient Education in a 14-month Randomised Trial Fails to Improve Adherence in Ulcerative Colitis: Influence of Demographic and Clinical Parameters on Non-adherence. Journal of Crohn's and Colitis, 2017, 11, 1052-1062.	1.3	17
123	Efficacy and safety of rectal 5-aminosalicylic acid versus corticosteroids in active distal ulcerative colitis: a systematic review and network meta-analysis. Scientific Reports, 2017, 7, 46693.	3.3	8
124	Systematic review with meta-analysis: proximal disease extension in limited ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2017, 45, 1481-1492.	3.7	55
125	Patient-Reported Outcomes of Quality of Life, Functioning, and GI/Psychiatric Symptom Severity in Patients with Inflammatory Bowel Disease (IBD). Inflammatory Bowel Diseases, 2017, 23, 798-803.	1.9	56
126	A Novel User-Friendly Model to Predict Corticosteroid Utilization in Newly Diagnosed Patients with Ulcerative Colitis. Inflammatory Bowel Diseases, 2017, 23, 991-997.	1.9	10
127	Ulcerative proctitis is a frequent location of paediatric-onset UC and not a minor disease: a population-based study. Gut, 2017, 66, 1912-1917.	12.1	24
128	Risk factors for proximal disease extension and colectomy in left-sided ulcerative colitis. United European Gastroenterology Journal, 2017, 5, 554-562.	3.8	27



#	ARTICLE	IF	CITATIONS
129	Clinical presentation of Crohn's, ulcerative colitis, and indeterminate colitis: Symptoms, extraintestinal manifestations, and disease phenotypes. <i>Seminars in Pediatric Surgery</i> , 2017, 26, 349-355.	1.1	224
130	Fatigue in a population-based cohort of patients with inflammatory bowel disease 20 years after diagnosis: The IBSEN study. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 351-358.	1.5	52
131	Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD "AGED study". <i>Digestive and Liver Disease</i> , 2017, 49, 17-23.	0.9	35
132	The Disease Burden and Clinical Characteristics of Inflammatory Bowel Disease in the Chinese Population: A Systematic Review and Meta-Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2017, 14, 238.	2.6	62
133	Visceral Inflammation and Immune Activation Stress the Brain. <i>Frontiers in Immunology</i> , 2017, 8, 1613.	4.8	50
134	Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 662-669.	1.3	56
135	Colectomy Rates in Ulcerative Colitis are Low and Decreasing: 10-year Follow-up Data From the Swiss IBD Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 811-818.	1.3	88
136	Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case-control study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 605-614.	3.7	57
137	Efficacy of Home Telemonitoring versus Conventional Follow-up: A Randomized Controlled Trial among Teenagers with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 432-441.	1.3	46
138	Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2291-2302.	1.9	22
139	Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study. <i>Journal of Gastroenterology</i> , 2018, 53, 494-506.	5.1	20
140	Serial semi-quantitative measurement of fecal calprotectin in patients with ulcerative colitis in remission. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 152-157.	1.5	16
141	Inflammatory Bowel Disease. <i>Gastroenterology Clinics of North America</i> , 2018, 47, 755-772.	2.2	34
142	The Transient Receptor Potential Vanilloid 1 Is Associated with Active Inflammation in Ulcerative Colitis. <i>Mediators of Inflammation</i> , 2018, 2018, 1-7.	3.0	13
143	Endoscopic Evaluation of Surgically Altered Bowel in Patients With Inflammatory Bowel Diseases. , 2018, , 141-159.		0
144	Refractory ulcerative proctitis: How to treat it?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 32-33, 49-57.	2.4	24
145	Biological therapy and surgery rates in inflammatory bowel diseases " Data analysis of almost 1000 patients from a Hungarian tertiary IBD center. <i>PLoS ONE</i> , 2018, 13, e0200824.	2.5	6
146	Relapse Prevention in Ulcerative Colitis by Plant-Based Diet Through Educational Hospitalization: A Single-Group Trial. , 2018, 22, 17-167.		19

#	ARTICLE	IF	CITATIONS
147	Caspase recruitment domain (CARD) family (CARD9, CARD10, CARD11, CARD14 and CARD15) are increased during active inflammation in patients with inflammatory bowel disease. <i>Journal of Inflammation</i> , 2018, 15, 13.	3.4	19
148	Validation of the "German Inflammatory Bowel Disease Activity Index (GIBDI)" An Instrument for Patient-Based Disease Activity Assessment in Crohn's Disease and Ulcerative Colitis. <i>Zeitschrift Fur Gastroenterologie</i> , 2018, 56, 1267-1275.	0.5	4
149	Surgery in ulcerative colitis: When? How?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 32-33, 71-78.	2.4	56
150	A systems pharmacology model for inflammatory bowel disease. <i>PLoS ONE</i> , 2018, 13, e0192949.	2.5	27
151	Continuous Clinical Response Is Associated With a Change of Disease Course in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 163-171.	1.9	6
153	British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. <i>Cut</i> , 2019, 68, s1-s106.	12.1	1,353
154	Baseline risk assessment of patients with ulcerative colitis: does initial treatment selection influence outcomes?. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 80-85.	1.6	1
155	Genetic Studies of Inflammatory Bowel Disease-Focusing on Asian Patients. <i>Cells</i> , 2019, 8, 404.	4.1	52
156	Relapse Prevention by Plant-Based Diet Incorporated into Induction Therapy for Ulcerative Colitis: A Single-Group Trial. , 2019, 23, .		26
157	Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1301-1313.	3.7	30
158	Very Early Onset Inflammatory Bowel Disease (VEOIBD). , 2019, , 383-404.		0
159	Time to include patients with ulcerative proctitis in clinical trials. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 900-902.	8.1	5
160	Big data in IBD: a look into the future. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 312-321.	17.8	103
161	Appendectomy for Therapy-Refractory Ulcerative Colitis Results in Pathological Improvement of Colonic Inflammation: Short-Term Results of the PASSION Study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 165-171.	1.3	34
162	Discovery and validation of mucosal TNF expression combined with histological score - a biomarker for personalized treatment in ulcerative colitis. <i>BMC Gastroenterology</i> , 2020, 20, 321.	2.0	8
163	Surgical Management of Ulcerative Colitis. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 753-768.	2.2	9
164	Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 2080-2087.	2.8	11
165	Gene Expression Profiling of Mediators Associated with the Inflammatory Pathways in the Intestinal Tissue from Patients with Ulcerative Colitis. <i>Mediators of Inflammation</i> , 2020, 2020, 1-11.	3.0	23

#	ARTICLE	IF	CITATIONS
166	Disease Activity Patterns in the First 5 Years After Diagnosis in Children With Ulcerative Colitis: A Population-Based Study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 367-374.	1.3	5
167	Increased expression of extracellular matrix metalloproteinase inducer (EMMPRIN) and MMP10, MMP23 in inflammatory bowel disease: Cross-sectional study. <i>Scandinavian Journal of Immunology</i> , 2021, 93, e12962.	2.7	12
168	Dental pulp stem cells overexpressing hepatocyte growth factor facilitate the repair of DSS-induced ulcerative colitis. <i>Stem Cell Research and Therapy</i> , 2021, 12, 30.	5.5	14
169	Predicting Outcome in Acute Severe Colitis—Controversies in Clinical Practice in 2021. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1211-1221.	1.3	17
170	The Burden of Inflammatory Bowel Disease in Europe in 2020. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1573-1587.	1.3	160
171	Predicting Therapeutic Response in Pediatric Ulcerative Colitis—A Journey Towards Precision Medicine. <i>Frontiers in Pediatrics</i> , 2021, 9, 634739.	1.9	7
172	Tasas de colectomía en colitis ulcerosa 15 años después del diagnóstico. Datos de la cohorte Navarra 2001-2003. <i>Gastroenterología y Hepatología</i> , 2022, 45, 1-8.	0.5	4
173	Drug development for ulcerative proctitis: current concepts. <i>Gut</i> , 2021, 70, 1203-1209.	12.1	7
174	Evaluation of the efficacy of MMX mesalazine therapy for moderate ulcerative colitis. <i>Meditinskiy Sovet</i> , 2021, , 113-123.	0.5	3
175	ECCO Topical Review: Refractory Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1605-1620.	1.3	16
177	Ulcerative Proctitis and Anorectal Crohn's Disease. , 2019, , 531-554.		1
178	Moderate-to-severe Endoscopic Inflammation is Frequent After Clinical Remission in Pediatric Ulcerative Colitis. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2021, 72, 569-573.	1.8	3
179	Incidence of Ulcerative Colitis Relapse: A Prospective Cohort Study in Southern Iran. <i>Annals of Colorectal Research</i> , 2016, 4, .	0.1	5
180	Social and demographic characteristics, features of disease course and treatment options of inflammatory bowel disease in Russia: results of two multicenter studies. <i>Al'manah Klinicheskoy Meditsiny</i> , 2018, 46, 445-463.	0.3	41
181	Framework for assessing quality of care for inflammatory bowel disease in Sweden. <i>World Journal of Gastroenterology</i> , 2012, 18, 1085.	3.3	17
182	Clinical characteristics and treatment of inflammatory bowel disease: A comparison of Eastern and Western perspectives. <i>World Journal of Gastroenterology</i> , 2014, 20, 11525.	3.3	102
183	Dietary and metabolomic determinants of relapse in ulcerative colitis patients: A pilot prospective cohort study. <i>World Journal of Gastroenterology</i> , 2017, 23, 3890.	3.3	28
184	Albumin as a prognostic marker for ulcerative colitis. <i>World Journal of Gastroenterology</i> , 2017, 23, 8008-8016.	3.3	50

#	ARTICLE	IF	CITATIONS
185	Predictive factors for a severe clinical course in ulcerative colitis: Results from population-based studies. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2016, 7, 235.	1.1	29
186	Should maintenance therapy be performed in ulcerative proctitis? How long should it be continued?. Turkish Journal of Gastroenterology, 2012, 23, 21-24.	1.1	2
187	Clinical course and predictors of total colectomy in ulcerative colitis; a referral center experience from Turkey. Turkish Journal of Gastroenterology, 2015, 26, 25-30.	1.1	8
188	Fecal Calprotectin is an Accurate Tool and Correlated to Seo Index in Prediction of Relapse in Iranian Patients With Ulcerative Colitis. Iranian Red Crescent Medical Journal, 2015, 17, e22796.	0.5	11
189	Biologicals in treatment of acute ulcerative colitis. Tropical Gastroenterology: Official Journal of the Digestive Diseases Foundation, 2015, 36, 80-85.	0.0	9
190	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment. Journal of Crohn's and Colitis, 2022, 16, 179-189.	1.3	120
191	Statistical Analysis of The Risk Factor of Colitic Cancer in UC Patients using Tree Model. Nihon Daicho Komonbyo Gakkai Zasshi, 2010, 63, 407-414.	0.0	0
192	The Incidence of Proximal Extension of Ulcerative Proctitis in Japan and Factors Related to Proximal Extension. The Showa University Journal of Medical Sciences, 2011, 23, 11-21.	0.1	0
193	Chronisch-entzündliche Darmerkrankungen (CED). , 2013, , 333-361.		0
194	The Natural History of Ulcerative Colitis. , 2014, , 23-30.		0
195	What Happens If I Do Nothing for My Ulcerative Colitis? The Natural History of Untreated Ulcerative Colitis. , 2015, , 41-51.		0
196	Surgical outcomes of Korean ulcerative colitis patients with and without colitis-associated cancer. World Journal of Gastroenterology, 2015, 21, 3547.	3.3	5
198	Outcome of Ulcerative Colitis 20 Years after Diagnosis in a Prospective Population-based Inception Cohort from South-Eastern Norway, the IBSEN Study. Journal of Crohn's and Colitis, 2021, 15, 969-979.	1.3	29
199	State-of-the-Art Lecture: Future therapies in inflammatory bowel diseases. , 0, , 232-242.		0
200	Endoscopic and histologic findings in pediatric inflammatory bowel disease. Gastroenterology and Hepatology, 2010, 6, 174-80.	0.1	9
201	Predictors of aggressive inflammatory bowel disease. Gastroenterology and Hepatology, 2011, 7, 652-9.	0.1	31
202	Health-related quality of life in patients with inflammatory bowel disease: a single-center experience. Annals of Gastroenterology, 2013, 26, 243-248.	0.6	30
203	Treatment Targets in Ulcerative Colitis: Is It Time for All In, including Histology?. Journal of Clinical Medicine, 2021, 10, 5551.	2.4	9

#	ARTICLE	IF	CITATIONS
204	Chronisch entzündliche Darmerkrankungen: Tipps für eine differenzierte Biologika-Auswahl. , 0, , .		0
205	What Does Disease Progression Look Like in Ulcerative Colitis, and How Might It Be Prevented?. Gastroenterology, 2022, 162, 1396-1408.	1.3	49
206	When disease extent is not always a key parameter: Management of refractory ulcerative proctitis. Current Research in Pharmacology and Drug Discovery, 2022, 3, 100071.	3.6	1
207	Colectomy rate in ulcerative colitis 15 years after diagnosis: Results from the 2001-2003 Navarra cohort. Gastroenterology Y Hepatology (English Edition), 2022, 45, 1-8.	0.1	0
208	Factors Predictive of Proximal Disease Extension and Clinical Course of Patients Initially Diagnosed with Ulcerative Proctitis in an IBD Referral Center. , 2022, 33, 320-328.		0
209	Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: Data from the open-label, long-term extension study, <scp>OCTAVE</scp> open. Alimentary Pharmacology and Therapeutics, 2022, , .	3.7	5
210	Combining biological therapies in patients with inflammatory bowel disease: a Finnish multi-centre study. Scandinavian Journal of Gastroenterology, 2022, 57, 936-941.	1.5	7
211	A Clinical Predictive Model for One-year Colectomy in Adults Hospitalized for Severe Ulcerative Colitis. Crohn's & Colitis 360, 2022, 4, .	1.1	2
214	The Asia-Pacific Consensus on Ulcerative Colitis. Journal of Gastroenterology and Hepatology (Australia), 2009, , no-no.	2.8	0
215	İnflamatuvar barsak hastalıkları olan hastalarda klinik özellikler, tedavi seçenekleri ve komplikasyonların değerlendirilmesi. Family Practice and Palliative Care, 0, , 64-70.	0.3	0
216	Prediction of long-term remission in patients following discontinuation of anti-TNF therapy in ulcerative colitis: a 10-year follow up study. BMC Gastroenterology, 2022, 22, .	2.0	3
217	Disease clearance in ulcerative colitis: Setting the therapeutic goals for future in the treatment of ulcerative colitis. Frontiers in Medicine, 0, 9, .	2.6	7
218	The Full Picture of Ulcerative Colitis: The Burden, the Patient, the Treatment. European Medical Journal Gastroenterology, 0, , 58-64.	0.0	0
219	Clinical and Demographic Features and Treatment Approaches for Inflammatory Bowel Diseases (Crohn's Disease, Ulcerative Colitis) in the Russia. The Primary Results of the Analysis of the National Register. Koloproktologia, 2023, 22, 65-82.	0.6	5
220	Low Adherence is Associated with Chronic Active Disease in Ulcerative Colitis: A Retrospective Study from a Single Referral Center. Patient Preference and Adherence, 0, Volume 17, 807-816.	1.8	2
221	Krankheitsbewältigung bei Colitis ulcerosa: Die therapeutischen Ziele für die Zukunft bei der Behandlung von Colitis ulcerosa. Karger Kompass Autoimmun, 2023, 5, 61-66.	0.0	0
223	Temporal Trends of Inflammatory Bowel Disease Burden in China from 1990 to 2030 with Comparisons to Japan, South Korea, the European Union, the United States of America, and the World. Clinical Epidemiology, 0, Volume 15, 583-599.	3.0	4
224	Clinical Features and Natural History of Paediatric Patients with Ulcerative Proctitis: A Multicentre Study from the Paediatric IBD Porto Group of ESPGHAN. Journal of Crohn's and Colitis, 2023, 17, 1939-1948.	1.3	0

#	ARTICLE	IF	CITATIONS
226	Clusters of Disease Activity and Early Risk Factors of Clinical Course of Pediatric Crohn’s Disease. Inflammatory Bowel Diseases, 0, , .	1.9	0
227	Emergency colectomy for massive rectal bleeding in a patient with well-controlled ulcerative colitis receiving Vedolizumab. Archive of Clinical Cases, 2023, 10, 133-137.	0.5	0
228	The influence of sleep factors and dietary habits on the disease pattern of ulcerative colitis patients with long and short disease courses – a multicentre cross-sectional analysis. Annals of Medicine, 2024, 56, .	3.8	0